186 related articles for article (PubMed ID: 38609450)
1. CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer.
Yang K; Ma Y; Chen W; Liu L; Yang Z; He C; Zheng N; Liu X; Cheng X; Song J; Chen Y; Qiao H; Zhang R
Sci Rep; 2024 Apr; 14(1):8575. PubMed ID: 38609450
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive pan-cancer analysis reveals CCDC58 as a carcinogenic factor related to immune infiltration.
Wu H; Geng Q; Shi W; Qiu C
Apoptosis; 2024 Apr; 29(3-4):536-555. PubMed ID: 38066393
[TBL] [Abstract][Full Text] [Related]
3. Coiled-coil domain-containing protein 58 (CCDC58) is a novel prognostic biomarker correlated with mitochondrial functions in hepatocellular carcinoma.
Chen L; Zhang J; Yang Y; Shu J; Zheng J; Zhan X; Guo M
Am J Transl Res; 2023; 15(4):2568-2584. PubMed ID: 37193151
[TBL] [Abstract][Full Text] [Related]
4. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
[TBL] [Abstract][Full Text] [Related]
6. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
[TBL] [Abstract][Full Text] [Related]
8. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
Wang Y; Liu T; Zhang K; Huang RH; Jiang L
Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
[TBL] [Abstract][Full Text] [Related]
10. Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma.
Wu SY; Liao P; Yan LY; Zhao QY; Xie ZY; Dong J; Sun HT
BMC Gastroenterol; 2021 Nov; 21(1):416. PubMed ID: 34724892
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer.
Zhong H; Shi Q; Wen Q; Chen J; Li X; Ruan R; Zeng S; Dai X; Xiong J; Li L; Lei W; Deng J
Front Immunol; 2023; 14():1058627. PubMed ID: 36923407
[TBL] [Abstract][Full Text] [Related]
12. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
13. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
14. Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy.
Cui Z; Zou F; Wang R; Wang L; Cheng F; Wang L; Pan R; Guan X; Zheng N; Wang W
World J Surg Oncol; 2023 Sep; 21(1):309. PubMed ID: 37759234
[TBL] [Abstract][Full Text] [Related]
15. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis.
Han X; Long W; Liu Y; Xu J
Front Surg; 2022; 9():985034. PubMed ID: 36338652
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma.
Lin YR; Yang WJ; Yang GW
Aging (Albany NY); 2021 May; 13(9):12929-12954. PubMed ID: 33952716
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
19. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
